FDA issues draft guidance on CAM products
The FDA is announcing the availability of a draft guidance for industry entitled "Complementary and Alternative Medicine [CAM] Products and Their Regulation by the FDA." The draft guidance discusses when a CAM product is subject to the Federal Food, Drug, and Cosmetic Act or Public Health Service Act. Electronic comments may be submitted by April 30 to
Recent Videos
Related Content
FDA’s Recent Exemptions: What Do They Mean as We Finalize DSCSA Implementation?
October 31st 2024Podcast
Kala Shankle, Vice President of Regulatory Affairs with the Healthcare Distribution Alliance, and Ilisa Bernstein, President of Bernstein Rx Solutions, LLC, discussed recent developments regarding the Drug Supply Chain Security Act.
